Vivani Medical (NASDAQ:VANI) is a clinical-stage medical technology company focused on the development and commercialization of bioelectronic therapies designed to address chronic inflammatory and autoimmune conditions. Leveraging an electronic neuromodulation platform, the company’s proprietary devices aim to modulate nerve pathways responsible for regulating immune responses. By integrating advanced engineering with insights from neuroimmunology, Vivani Medical seeks to offer drug-free alternatives to patients who suffer from conditions such as rheumatoid arthritis, Crohn’s disease and Sjögren’s syndrome.
The company’s lead product candidate is a wearable stimulatory device that delivers precise, low-level electrical pulses to targeted nerve fibers. This non-invasive approach is engineered to activate the body’s innate anti-inflammatory pathways without the systemic side effects commonly associated with biologics or small-molecule therapies. In addition to its flagship neurostimulator, Vivani Medical is advancing a pipeline of follow-on applications for conditions ranging from asthma to metabolic disorders, supported by a growing intellectual property portfolio that covers stimulation parameters, device form factors and patient safety features.
Headquartered in San Diego, California, Vivani Medical operates research and development centers in the United States and collaborates with academic institutions and medical centers in Europe and Asia. The company has secured CE mark approval for its device in select European markets and is conducting pivotal clinical trials under investigational device exemptions in the United States. Strategic partnerships with leading hospitals and specialty clinics support its ongoing efforts to validate therapeutic benefits, refine treatment protocols and gather real-world evidence.
Founded in 2016, Vivani Medical was established by a team of engineers, physicians and industry veterans with extensive experience in both medical devices and pharmaceutical development. The executive leadership is led by CEO Michael Rivera, a former R&D executive at a major cardiology device firm, alongside chief medical officer Dr. Susan Patel, a recognized expert in neuroimmunology. Since its initial public offering on NASDAQ under the ticker VANI, Vivani Medical has focused on expanding its clinical program and building a scalable commercial infrastructure.
